The problem we solve: Currently there is no effective treatment for COvid-19. Additionally health condition like cancer, tuberclosis, respiratiory diseases can be effectively treated using this novel combination.
About our solution: The goal of this product is to substantiate potential antimicrobial bio-silverformulation to deliver plant-derived antiviral alkaloid (Cepharanthine (CEP)) by inhalation, to minimise the aggravation of respiratory system infections caused by SARS-CoV-2. This product aims at the major contribution that nanotechnology solutions can bring to mitigate the acute and chronic effects of COVID-19 pandemic from the protection and medication point of view by potentially blocking viral replication of SARS-CoV-2. This product containing silver nanoparticles with the size in the range of less than 100 nm and coated with polyethylene glycol (PEG) can be deliver in the form of dry powder inhaler via oral inhalation in the form of single use capsules or multi-dose inhalers such as sunhaler or Advair diskus. We proclaim that for significant antiviral effectiveness the size of silver nanoparticlesneeds to be less than 100nm, preferably in the range 15nm-70nm size.Progress to date:
BioSilver,CEP and PEG order has been placed with vendors and to be combined at Adhya BioScience
Provisional Patent has been filed and now IP protection of the formulation is protected for 12 months
Creator: Subhramani Naidu
Bio: A business researcher with top tier investment banking having expertise across sectors and geographies.
Dr Shrinidh Joshi
Scientific Advisor, PHD
Biography: An accomplished US based scientist, currently Technical Project leader with leading MNC. Also startup ACe2Stem focusing on Angiotensin and stem cell regeneration.
Title: Scientific Advisor
Advanced Degree(s): PHD
Dr. Varaprasad . Bobbarala
Chief Scientist & Director. Adhya Biosciences Pvt. Ltd, PhD
Biography: Dr Varaparasad is the an eminient scientist and Director of Adhya bioscience. Please follow the link to know more about his research papers: https://scholar.google.co.in/citations?user=C4cFOlIAAAAJ&hl=en
Title: Chief Scientist & Director. Adhya Biosciences Pvt. Ltd
Advanced Degree(s): PhD
COVID Problem We Address
Effective treatment for Covid is producted by our product. Both biosilver and Cepharanthine are known ingredients with well documented studies on the efficacy against virus in vitro as well as having a good safety profile. Our product can be either a standalone medicine or can be included in the prescription list for Covid patients along with regular drugs to reduce viral load.
Our COVID Solution
Our product is precisely engineered to target corona virus membrane. Silver binds to gylcoprotien in virus envelope and CEP also interacts with gylcoprotiens and stops virus from replicating. This double attack strategy of focussing on a common point of gylcoprotiens by both the ingredient of our product may result in better disruption of the viral membrane as compared to current market products. Additionally CEP is also anti-inflamatory which will reduce the cytokine releases.
Covid Therapy is worldwide multibillion dollar opportunity
TB Drugs Market Size Worth $1.38 Billion By 2025 | CAGR: 5.2% The global tuberculosis drugs/therapeutics (TB) market size is expected to reach USD 1.38 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 5.2% during the forecast period
Further market exists for Cancer, Hairloss etc.
Both ingredients of the drug combination has well known and documented efficiacy against Covid aand Tuberclosis.
This nano delivery system of Biosilver containing payload of CEP is a silver bullet for multiple health condition
Projected 3 Year Growth
We anticipate 10% market penetration of TB which can be estimated upto $30 million in revenue.
Covid Therapy on successful trials can up the value of the firm by multiple times.
We plan to retain brand and Intellectual property outsourcing the manufacturing process to suitable firm. We are in the process of possible ways of commercialisation through a Biotech Innovation specialist Ploemen LifeSicence consultancy who has recommeded developing the product. Further Adhya BioScience will be conduct synthesis formulation and oversee the product development.
There are 70 coompanies which have trials in Covid. Our product is based on validated and documented research on its effectiveness iin Covid. It can get fast track approval and even incase Corona anitvirus is launched, it still has application in Tuberclosis, Cancer, and other health condition. We think its a silver bullet to several health condition and hence we will have a steady market.
Adhya Bioscience to formulate and oversee to enhance product properties.
Pranada Biopharma to do the marketing and clinical trials of the product.
Biotech consultancy from Nederland, USA and France have validated the product as innovative strategy.
Please note that access to the company's confidential materials is limited. Click this button to request access from the Company and its representatives.
Help us find best new ideas to fund by telling us what you think. Your feedback goes straight to the team behind this project in private, so tell them what you really think.